Possible therapeutic options and management of COVID-19

Detalhes bibliográficos
Autor(a) principal: Ayobami Matthew, Olajuyin
Data de Publicação: 2022
Outros Autores: Adefunke Kafayat, Olajuyin, Ayodeji Mathias, Adegoke, Saliu, Jamiyu Ayodeji, Hayatu, Raji Muhammed, Malachy, Okeke Ifeanyi, Xiaoju, Zhang
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/28002
Resumo: Currently, there is no effective therapy against Coronavirus disease 2019 (COVID-19). Thus, there is crucial requirement for effective therapy against COVID-19. To our knowledge, few investigations have been conducted on AT2 progenitor cells as target for the (SARS-CoV-2). Hence, alveolar type 2 progenitor cells may be a possible therapeutic agent against COVID19. This review focused on the pathogenesis and pathophysiology of COVID19 disease on AT2 cells and explored potential mechanisms to prevent infection and death of AT2 progenitor cells as possible therapy against COVID-19. We propose that inhibition of IL-1 receptor, IL 1, NFkB and JNK signalling pathway may serve as therapeutic target for COVID-19
id UNIFEI_75d7990942e80b3c968ae0c296b5f4ac
oai_identifier_str oai:ojs.pkp.sfu.ca:article/28002
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Possible therapeutic options and management of COVID-19Posibles opciones terapéuticas y manejo de la COVID-19Possíveis opções terapêuticas e gestão da COVID-19COVID-19Alveolar type 2PathogenesisTherapeutic.COVID-19Alveolar tipo 2PatogêneseTerapêutica.COVID-19Alveolar tipo 2PatogeniaTerapéutica.Currently, there is no effective therapy against Coronavirus disease 2019 (COVID-19). Thus, there is crucial requirement for effective therapy against COVID-19. To our knowledge, few investigations have been conducted on AT2 progenitor cells as target for the (SARS-CoV-2). Hence, alveolar type 2 progenitor cells may be a possible therapeutic agent against COVID19. This review focused on the pathogenesis and pathophysiology of COVID19 disease on AT2 cells and explored potential mechanisms to prevent infection and death of AT2 progenitor cells as possible therapy against COVID-19. We propose that inhibition of IL-1 receptor, IL 1, NFkB and JNK signalling pathway may serve as therapeutic target for COVID-19Actualmente, no existe una terapia efectiva contra la enfermedad por coronavirus 2019 (COVID-19). Por lo tanto, existe un requisito crucial para una terapia eficaz contra COVID-19. Hasta donde sabemos, se han realizado pocas investigaciones sobre las células progenitoras AT2 como objetivo para el (SARS-CoV-2). Por lo tanto, las células progenitoras alveolares tipo 2 pueden ser un posible agente terapéutico contra COVID19. Esta revisión se centró en la patogenia y la fisiopatología de la enfermedad COVID19 en las células AT2 y exploró los posibles mecanismos para prevenir la infección y la muerte de las células progenitoras AT2 como posible terapia contra la COVID-19. Proponemos que la inhibición de la vía de señalización del receptor IL-1, IL 1, NFkB y JNK puede servir como diana terapéutica para COVID-19.Atualmente, não existe uma terapia eficaz contra a doença de Coronavírus 2019 (COVID-19). Assim, há um requisito crucial para uma terapia eficaz contra o COVID-19. Até onde sabemos, poucas investigações foram conduzidas em células progenitoras AT2 como alvo para o (SARS-CoV-2). Assim, as células progenitoras alveolares tipo 2 podem ser um possível agente terapêutico contra o COVID19. Esta revisão se concentrou na patogênese e fisiopatologia da doença COVID19 em células AT2 e explorou mecanismos potenciais para prevenir a infecção e morte de células progenitoras AT2 como possível terapia contra COVID-19. Propomos que a inibição da via de sinalização do receptor de IL-1, IL 1, NFkB e JNK pode servir como alvo terapêutico para COVID-19.Research, Society and Development2022-04-14info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2800210.33448/rsd-v11i5.28002Research, Society and Development; Vol. 11 No. 5; e47711528002Research, Society and Development; Vol. 11 Núm. 5; e47711528002Research, Society and Development; v. 11 n. 5; e477115280022525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/28002/24783Copyright (c) 2022 Olajuyin Ayobami Matthew; Olajuyin Adefunke Kafayat; Adegoke Ayodeji Mathias; Jamiyu Ayodeji Saliu; Raji Muhammed Hayatu; Okeke Ifeanyi Malachy; Zhang Xiaojuhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessAyobami Matthew, Olajuyin Adefunke Kafayat, Olajuyin Ayodeji Mathias, AdegokeSaliu, Jamiyu Ayodeji Hayatu, Raji Muhammed Malachy, Okeke Ifeanyi Xiaoju, Zhang 2022-04-17T18:18:56Zoai:ojs.pkp.sfu.ca:article/28002Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:45:33.610527Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Possible therapeutic options and management of COVID-19
Posibles opciones terapéuticas y manejo de la COVID-19
Possíveis opções terapêuticas e gestão da COVID-19
title Possible therapeutic options and management of COVID-19
spellingShingle Possible therapeutic options and management of COVID-19
Ayobami Matthew, Olajuyin
COVID-19
Alveolar type 2
Pathogenesis
Therapeutic.
COVID-19
Alveolar tipo 2
Patogênese
Terapêutica.
COVID-19
Alveolar tipo 2
Patogenia
Terapéutica.
title_short Possible therapeutic options and management of COVID-19
title_full Possible therapeutic options and management of COVID-19
title_fullStr Possible therapeutic options and management of COVID-19
title_full_unstemmed Possible therapeutic options and management of COVID-19
title_sort Possible therapeutic options and management of COVID-19
author Ayobami Matthew, Olajuyin
author_facet Ayobami Matthew, Olajuyin
Adefunke Kafayat, Olajuyin
Ayodeji Mathias, Adegoke
Saliu, Jamiyu Ayodeji
Hayatu, Raji Muhammed
Malachy, Okeke Ifeanyi
Xiaoju, Zhang
author_role author
author2 Adefunke Kafayat, Olajuyin
Ayodeji Mathias, Adegoke
Saliu, Jamiyu Ayodeji
Hayatu, Raji Muhammed
Malachy, Okeke Ifeanyi
Xiaoju, Zhang
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ayobami Matthew, Olajuyin
Adefunke Kafayat, Olajuyin
Ayodeji Mathias, Adegoke
Saliu, Jamiyu Ayodeji
Hayatu, Raji Muhammed
Malachy, Okeke Ifeanyi
Xiaoju, Zhang
dc.subject.por.fl_str_mv COVID-19
Alveolar type 2
Pathogenesis
Therapeutic.
COVID-19
Alveolar tipo 2
Patogênese
Terapêutica.
COVID-19
Alveolar tipo 2
Patogenia
Terapéutica.
topic COVID-19
Alveolar type 2
Pathogenesis
Therapeutic.
COVID-19
Alveolar tipo 2
Patogênese
Terapêutica.
COVID-19
Alveolar tipo 2
Patogenia
Terapéutica.
description Currently, there is no effective therapy against Coronavirus disease 2019 (COVID-19). Thus, there is crucial requirement for effective therapy against COVID-19. To our knowledge, few investigations have been conducted on AT2 progenitor cells as target for the (SARS-CoV-2). Hence, alveolar type 2 progenitor cells may be a possible therapeutic agent against COVID19. This review focused on the pathogenesis and pathophysiology of COVID19 disease on AT2 cells and explored potential mechanisms to prevent infection and death of AT2 progenitor cells as possible therapy against COVID-19. We propose that inhibition of IL-1 receptor, IL 1, NFkB and JNK signalling pathway may serve as therapeutic target for COVID-19
publishDate 2022
dc.date.none.fl_str_mv 2022-04-14
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/28002
10.33448/rsd-v11i5.28002
url https://rsdjournal.org/index.php/rsd/article/view/28002
identifier_str_mv 10.33448/rsd-v11i5.28002
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/28002/24783
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 5; e47711528002
Research, Society and Development; Vol. 11 Núm. 5; e47711528002
Research, Society and Development; v. 11 n. 5; e47711528002
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052794021085184

Registros relacionados